{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:09:56Z","timestamp":1786975796001,"version":"build-2736575974"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1001\/jamapsychiatry.2018.4149","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T14:28:14Z","timestamp":1548858494000},"page":"409","source":"Crossref","is-referenced-by-count":23,"title":["Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide"],"prefix":"10.1001","volume":"76","author":[{"given":"Fran\u00e7ois","family":"Montastruc","sequence":"first","affiliation":[{"name":"Centre for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, Montreal, Qu\u00e9bec, Canada"},{"name":"Service de Pharmacologie M\u00e9dicale et Clinique, Centre Midi-Pyr\u00e9n\u00e9es de PharmacoVigilance, Pharmaco\u00e9pid\u00e9miologie et d'Informations sur le M\u00e9dicament, Centre Hospitalier Universitaire, Facult\u00e9 de M\u00e9decine, Toulouse, France"},{"name":"Unit\u00e9 clinique de Pharmacologie psychiatrique, Facult\u00e9 de M\u00e9decine, Centre Hospitalier Universitaire, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Nie","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Loo","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soham","family":"Rej","sequence":"additional","affiliation":[{"name":"Geri-PARTy Research Group, Department of Psychiatry, Jewish General Hospital, McGill University, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Dell\u2019Aniello","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Micallef","sequence":"additional","affiliation":[{"name":"Aix Marseille Univ, APHM, INSERM, Inst Neurosci Syst, Service de Pharmacologie Clinique et Pharmacovigilance, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Suissa","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, Montreal, Qu\u00e9bec, Canada"},{"name":"Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Renoux","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, Montreal, Qu\u00e9bec, Canada"},{"name":"Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Qu\u00e9bec, Canada"},{"name":"Department of Neurology and Neurosurgery, McGill University, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"yoi180101r1","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/archpsyc.60.10.974","article-title":"Mechanism of new antipsychotic medications: occupancy is not just antagonism.","volume":"60","author":"Grunder","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"yoi180101r2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2165\/11208400-000000000-00000","article-title":"Aripiprazole: a review of its use in the management of schizophrenia in adults.","volume":"26","author":"Croxtall","year":"2012","journal-title":"CNS Drugs"},{"issue":"10","key":"yoi180101r3","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.4088\/JCP.v66n1019h","article-title":"Treatment-emergent psychosis with aripiprazole.","volume":"66","author":"Barnas","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"yoi180101r4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/01.jcp.0000196417.44847.0b","article-title":"Aripiprazole as a dopamine partial agonist: positive and negative effects.","volume":"26","author":"Glick","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"yoi180101r5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3109\/13651501.2011.644300","article-title":"Severe psychotic exacerbation during combined treatment with aripiprazole\/haloperidol after prior treatment with risperidone.","volume":"16","author":"Letmaier","year":"2012","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"1","key":"yoi180101r6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1176\/ajp.2007.164.1.172a","article-title":"Manic episode during treatment with aripiprazole.","volume":"164","author":"Padala","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"1","key":"yoi180101r7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1017\/S1461145706006523","article-title":"Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole.","volume":"10","author":"Raja","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"issue":"7","key":"yoi180101r8","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1176\/appi.ajp.161.7.1308","article-title":"Worsening schizoaffective disorder with aripiprazole.","volume":"161","author":"Reeves","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"4","key":"yoi180101r9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000477313","article-title":"Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.","volume":"86","author":"Chouinard","year":"2017","journal-title":"Psychother Psychosom"},{"issue":"2","key":"yoi180101r10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00213-013-3154-1","article-title":"A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder.","volume":"228","author":"Takeuchi","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"yoi180101r11","doi-asserted-by":"publisher","first-page":"174","DOI":"10.2174\/1570159X14666160606093602","article-title":"Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review.","volume":"15","author":"Yin","year":"2017","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"yoi180101r12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/JCP.0b013e3181accfec","article-title":"Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study.","volume":"29","author":"Takeuchi","year":"2009","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"yoi180101r13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1177\/0269881115570083","article-title":"Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia.","volume":"29","author":"Takase","year":"2015","journal-title":"J Psychopharmacol"},{"issue":"2","key":"yoi180101r14","doi-asserted-by":"publisher","first-page":"17r11489","DOI":"10.4088\/JCP.17r11489","article-title":"Can Aripiprazole Worsen Psychosis in Schizophrenia? A Meta-Analysis of Double-Blind, Randomized, Controlled Trials.","volume":"79","author":"Takeuchi","year":"2018","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"yoi180101r15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1192\/bjp.bp.109.070961","article-title":"Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used.","volume":"197","author":"Pope","year":"2010","journal-title":"Br J Psychiatry"},{"issue":"7","key":"yoi180101r16","doi-asserted-by":"publisher","first-page":"e005535","DOI":"10.1136\/bmjopen-2014-005535","article-title":"Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study.","volume":"4","author":"Hughes","year":"2014","journal-title":"BMJ Open"},{"issue":"12","key":"yoi180101r17","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.4088\/JCP.v67n1215","article-title":"Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics.","volume":"67","author":"Moeller","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"yoi180101r18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1192\/bjp.bp.116.182683","article-title":"Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?","volume":"209","author":"Murray","year":"2016","journal-title":"Br J Psychiatry"},{"issue":"3","key":"yoi180101r19","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data Resource Profile: Clinical Practice Research Datalink (CPRD).","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"issue":"5","key":"yoi180101r21","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1592\/phco.23.5.686.32205","article-title":"Validity of the general practice research database.","volume":"23","author":"Jick","year":"2003","journal-title":"Pharmacotherapy"},{"issue":"3","key":"yoi180101r22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/pubmed\/21.3.299","article-title":"Clinical information for research; the use of general practice databases.","volume":"21","author":"Lawrenson","year":"1999","journal-title":"J Public Health Med"},{"issue":"6779","key":"yoi180101r23","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1136\/bmj.302.6779.766","article-title":"Validation of information recorded on general practitioner based computerised data resource in the United Kingdom.","volume":"302","author":"Jick","year":"1991","journal-title":"BMJ"},{"issue":"4","key":"yoi180101r24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/pds.v26.4","article-title":"Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores.","volume":"26","author":"Suissa","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"yoi180101r25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/bcp.2013.76.issue-1","article-title":"Validation of suicide and self-harm records in the Clinical Practice Research Datalink.","volume":"76","author":"Thomas","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"yoi180101r26","doi-asserted-by":"publisher","first-page":"f5704","DOI":"10.1136\/bmj.f5704","article-title":"Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study.","volume":"347","author":"Thomas","year":"2013","journal-title":"BMJ"},{"issue":"408","key":"yoi180101r27","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The Robust Inference for the Cox Proportional Hazards Model.","volume":"84","author":"Lin","year":"1989","journal-title":"J Am Stat Assoc"},{"key":"yoi180101r20","unstructured":"NHS Digital. Read Codes. https:\/\/digital.nhs.uk\/services\/terminology-and-classifications\/read-codes. Accessed December 20, 2018."},{"key":"yoi180101r28","unstructured":"US Food and Drug Administration. What is a Serious Adverse Event? https:\/\/www.fda.gov\/safety\/medwatch\/howtoreport\/ucm053087.htm. Accessed May 28, 2018."}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamapsychiatry\/article-pdf\/76\/4\/409\/17420130\/jamapsychiatry_montastruc_2019_oi_180101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T14:24:55Z","timestamp":1554301495000},"score":1,"resource":{"primary":{"URL":"http:\/\/archpsyc.jamanetwork.com\/article.aspx?doi=10.1001\/jamapsychiatry.2018.4149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.4149","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,1]]}}}